158435-41-7Relevant academic research and scientific papers
Stilbene Boronic Acids Form a Covalent Bond with Human Transthyretin and Inhibit Its Aggregation
Smith, Thomas P.,Windsor, Ian W.,Forest, Katrina T.,Raines, Ronald T.
, p. 7820 - 7834 (2017/10/06)
Transthyretin (TTR) is a homotetrameric protein. Its dissociation into monomers leads to the formation of fibrils that underlie human amyloidogenic diseases. The binding of small molecules to the thyroxin-binding sites in TTR stabilizes the homotetramer and attenuates TTR amyloidosis. Herein, we report on boronic acid-substituted stilbenes that limit TTR amyloidosis in vitro. Assays of affinity for TTR and inhibition of its tendency to form fibrils were coupled with X-ray crystallographic analysis of nine TTR·ligand complexes. The ensuing structure-function data led to a symmetrical diboronic acid that forms a boronic ester reversibly with serine 117. This diboronic acid inhibits fibril formation by both wild-type TTR and a common disease-related variant, V30M TTR, as effectively as does tafamidis, a small-molecule drug used to treat TTR-related amyloidosis in the clinic. These findings establish a new modality for covalent inhibition of fibril formation and illuminate a path for future optimization.
Diverse ortho-C(sp2)-H functionalization of benzaldehydes using transient directing groups
Liu, Xi-Hai,Park, Hojoon,Hu, Jun-Hao,Hu, Yan,Zhang, Qun-Liang,Wang, Bao-Long,Sun, Bing,Yeung, Kap-Sun,Zhang, Fang-Lin,Yu, Jin-Quan
supporting information, p. 888 - 896 (2017/05/16)
Pd-catalyzed C-H functionalizations promoted by transient directing groups remain largely limited to C-H arylation only. Herein, we report a diverse set of ortho-C(sp2)-H functionalizations of benzaldehyde substrates using the transient directing group strategy. Without installing any auxiliary directing group, Pd(II)-catalyzed C-H arylation, chlorination, bromination, and Ir(III)-catalyzed amidation, could be achieved on benzaldehyde substrates. The transient directing groups formed in situ via imine linkage can override other coordinating functional groups capable of directing C-H activation or catalyst poisoning, significantly expanding the scope for metal-catalyzed C-H functionalization of benzaldehydes. The utility of this approach is demonstrated through multiple applications, including late-stage diversification of a drug analogue.
Modulators of methyl modifying enzymes, compositions and uses thereof
-
Page/Page column 275; 276; 277, (2015/12/26)
Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.
2- PYRIDONE COMPOUND
-
Paragraph 0353; 0354, (2016/10/08)
PROBLEM TO BE SOLVED: To provide a compound that has excellent glucokinase (GK) activating action and is useful as a pharmaceutical. SOLUTION: The present invention provides a 2-pyridone compound represented by formula [1], and a tautomer or stereoisomer of the compound, or their pharmacologically acceptable salts, or their solvates (where R1 is RA-ZA-; RA is any of a carboxy group, a sulfo group or formula [5]). COPYRIGHT: (C)2016,JPOandINPIT
A new oxidovanadium(IV) complex containing an O, N-bidentate Schiff base ligand: Synthesis, characterization, crystal structure determination, thermal study and catalytic activity for an oxidative bromination reaction
Grivani, Gholamhossein,Tahmasebi, Vida,Khalaji, Aliakbar Dehno
, p. 144 - 150 (2013/12/04)
A new oxidovanadium(IV) schiff base complex (1) containing an ethyl bromide pendant group was synthesized by the reaction of the related bidentate O, N-Schiff base ligand and VO(acac)2 in a 2:1 ratio in methanol, under reflux conditions. The Schiff base ligand and its vanadyl Schiff base complex were characterized by 1H NMR and FT-IR spectra, and CHN analysis. The crystal structure of 1 was also determined by single crystal X-ray analysis. The vanadium center in this structure has a distorted tetragonal pyramidal N2O3 coordination sphere. The Schiff base ligand HL acts as a bidentate ligand by coordinating via the nitrogen atom of the imine group and the oxygen atom of the phenolic group, thereby forming a six-membered chelating ring. There are some non-classical inter- and intra-molecular hydrogen bonds of the type C-Ha?O and C-Ha?Br in 1. The catalytic activity of 1 was studied for the oxidative bromination of 2-nitrophenol as a model substrate. Different reaction parameters were studied in this reaction and the oxidative bromination of some organic compounds by a catalytic amount of 1 showed that it was an effective and selective catalyst under optimal conditions. Thermogravimeric analysis of 1 showed that it decomposed in two stages. In addition, complex 1 thermally decomposed in air at 660 C and the XRD pattern of the obtained solid showed the formation of V2O5 nanoparticles with an average size of 57 nm.
Synthesis, characterization, crystal structure, catalytic activity in oxidative bromination, and thermal study of a new oxidovanadium Schiff base complex containing O, N-bidentate Schiff base ligand
Grivani, Gholamhossein,Tahmasebi, Vida,Khalaji, Aliakbar Dehno,Eigner, Václav,Du?ek, Michal
, p. 3664 - 3677 (2015/10/19)
A new oxidovanadium(IV) Schiff base complex, VOL2 (1), HL = 2-{(E)-[2-(bromoethyl)imino]methyl}-6-methoxy phenol, containing ethyl bromide pendant group was synthesized by direct reaction of HL and VO(acac)2 in the ratio of 2: 1 in methanol at reflux. The Schiff base ligand and its vanadyl complex were characterized by FT-IR spectra and CHN analysis. Additionally, the Schiff base ligand has been characterized by 1H NMR spectroscopy. The crystal structure of 1 was also determined by single-crystal X-ray analysis, showing the distorted square-pyramidal N2O3 coordination around vanadium(IV). The catalytic activity of 1 was studied in the oxidative bromination of 2-nitrophenol as a model substrate, and different reaction parameters were investigated. The oxidative bromination of some organic compounds in the presence of 1 in optimal conditions showed that it was an effective and selective catalyst in those optimal conditions. Thermogravimetric analysis of 1 showed that it decomposed in two stages. 1 was thermally decomposed in air at 660 °C, and the XRD pattern of the obtained solid showed the formation of the V2O5 nanoparticles with average size of 34 nm.
MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
-
Paragraph 006309; 00632, (2013/06/05)
Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein
Reexamining hydroxamate inhibitors of botulinum neurotoxin serotype A: Extending towards the β-exosite
Smith, Garry R.,Caglic, Dejan,Capek, Petr,Zhang, Yan,Godbole, Sujata,Reitz, Allen B.,Dickerson, Tobin J.
supporting information; experimental part, p. 3754 - 3757 (2012/07/14)
Botulinum neurotoxins (BoNTs) are the most toxic proteins known to man, exposure to which results in flaccid paralysis. Given their extreme potency, these proteins have become studied as possible weapons of bioterrorism; however, effective treatments that function after intoxication have not progressed to the clinic. Here, we have reexamined one of the most effective inhibitors, 2,4-dichlorocinnamyl hydroxamate, in the context of the known plasticity of the BoNT/A light chain metalloprotease. Our studies have shown that modifications of this compound are tolerated and result in improved inhibitors, with the best compound having an IC50 of 0.23 μM. Given the inconsistency of structure-activity relationship trends observed across similar compounds, this data argues for caution in extrapolating across structural series.
NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS
-
Page/Page column 92; 93, (2010/09/07)
This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.
BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS
-
Page/Page column 14, (2009/04/25)
Compounds of formula (I) or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful inter alia for the treatment of obesity.
